Journal article

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Constantine S Tam, Hang Quach, Andrew Nicol, Xavier Badoux, Hannah Rose, H Miles Prince, Michael F Leahy, Richard Eek, Nicholas Wickham, Sushrut S Patil, Jane Huang, Radha Prathikanti, Aileen Cohen, Rebecca Elstrom, William Reed, Jingjing Schneider, Ian W Flinn

Blood Advances | AMER SOC HEMATOLOGY | Published : 2020

Abstract

Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or relapsed/refractory (R/R) follicular lymphoma (FL). In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL/SLL (n = 45) and FL (n = 36). Common adverse events (AEs) included upper respiratory tract infection (51%; n = 23), neutropenia (44%; n = 20), contusion (33%;..

View full abstract

Grants

Funding Acknowledgements

This work, including medical writing and editorial assistance, was supported by BeiGene USA, Inc. Writing and editorial support were provided by A. Daisy Goodrich and Bio Connections (Chicago, IL), funded by BeiGene USA, Inc. (San Mateo, CA).